JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
US$209.65
0.00%
(0.00) 1 天
US$212.71
arrow_upward
+1.46% (+3.06)today开盘前
休市： 10月14日, GMT-4 16:00:01 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 JAZZ 生成关键数据洞见…
市值
136.09亿
平均成交量
78.57万
成交量
9260.00
市盈率
14.33
52 周最高价
US$266.38
52 周最低价
US$128.80
每股收益
US$14.63
Beta 版
0.37
流通股数
6491.50万
员工人数
2890
市值
136.09亿
平均成交量
78.57万
成交量
9260.00
市盈率
14.33
52 周最高价
US$266.38
52 周最低价
US$128.80
每股收益
US$14.63
Beta 版
0.37
流通股数
6491.50万
员工人数
2890
新闻报道
来自网络来源和新闻合作伙伴
资料
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Jazz Pharmaceuticals PLC简介